The Challenge: Biotechnology Transfer to Public Health. Examples from Arbovirology

  • Thomas P. Monath


Infectious diseases remain the preeminent health problems in the developing world, and immunization the most effective approach to controlling them. Recombinant DNA technology has provided a plethora of new approaches for the development of vaccines. The priorities for development of new vaccines and delivery methods have been redefined by the Children’s Vaccine Initiative. Among the diseases targeted for vaccine improvement or development are three arbovirus infections, dengue, Japanese encephalitis, and yellow fever. The burden of disease caused by these mosquito-borne viruses, the current status of classical vaccines, and progress toward development of genetically-engineered vaccines are reviewed. Since 1984, the World Health Organization has promulgated research leading toward the development of molecular approaches to vaccines against these flaviviruses. Considerable headway has been made in the understanding of genome variation, the identification of protective epitopes, and in cloning and expression of relevant proteins in vaccinia and baculovirus systems. In addition, the development of full-length complementary DNA clones which yield infectious RNA transcripts is being pursued as a means of producing stable, attenuated and chimeric flavivirus vaccines.


Respiratory Syncytial Virus Dengue Fever Yellow Fever Dengue Hemorrhagic Fever Japanese Encephalitis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Henderson RH, Keja J (1989) Global control of vaccine-preventable diseases: how progress can be evaluated. Rev Infect Dis 11: 649CrossRefGoogle Scholar
  2. 2.
    Nakajima H (1990) Epidemiology and the future of the world. PAHO Epidemiol Bull 11 :1Google Scholar
  3. 3.
    Bektimirov T, Lambert P-H, Torrigiani G (1990) Vaccine development perspectives of the World Health Organization. J Med Virol 31: 62PubMedCrossRefGoogle Scholar
  4. 4.
    Anon (1990) Potential use of live viral and bacterial vectors for vaccines. WHO Meeting, Geneva, 19–22 June, 1989. Vaccine 8: 425Google Scholar
  5. 5.
    Institute of Medicine (1986) New Vaccine Development: Establishing Priorities. Vol II. Diseases of Importance in Developing Countries. Washington D.C., National Academy Press, 432 ppGoogle Scholar
  6. 6.
    Gubler DJ (1991) Dengue hemorrhagic fever: a global update. Virus Info Exch Newsletter 8: 2Google Scholar
  7. 7.
    Scott RMcN, Eckels KH, Bancroft WH, Summers PL, McCown JM, Anderson JH, Russell PK (1983) Dengue 2 vaccine: dose-response in volunteers in relation to yellow fever immune status. J Infect Dis 148: 1055PubMedCrossRefGoogle Scholar
  8. 8.
    Bhamarapratavi N, Yoksan S, Chayaniyayothin T, Angsubphakorn S, Bunyratvej A (1987) Immunization with a live attenuated dengue-2-virus candidate vaccine (16681-PDK 53) : clinical, immunological and biological responses in adult volunteers. Bull WHO 65: 189Google Scholar
  9. 9.
    Bhamarapratavi N, Yoksan S (1989) Study of bivalent dengue vaccine in volunteers. Lancet 1: 770Google Scholar
  10. 10.
    Brandt WE (1990) Development of dengue and Japanese encephalitis vaccines. J Infect Dis 162: 577PubMedCrossRefGoogle Scholar
  11. 11.
    Rice CM, Lenches EM, Eddy SR, Shin SJ, Sheets RL, Strauss JH (1985) Nucleotide sequence of yellow fever virus: implications for flavivirus gene expression and evolution. Science 229: 726PubMedCrossRefGoogle Scholar
  12. 12.
    Chambers TJ, Hahn CS, Galler R, Rice CM (1990) Flavivirus genome organization, expression and replication. Ann Rev Microbiol 44: 649CrossRefGoogle Scholar
  13. 13.
    Bray M, Zhao B, Markoff L, Eckels KH, Chanock RM, Lai CJ (1989) Mice immunized with recombinant vaccinia virus expressing dengue 4 virus structural proteins with or without nonstructural protein NS1 are protected against fatal dengue encephalitis. J Virol 63: 2853PubMedGoogle Scholar
  14. 14.
    Zhang Y M, Hayes EP, McCarty TC, Dubois DR, Summers PL, Eckels KH, Chanock RM, Lai CJ (1988) Immunization of mice with dengue structural proteins and nonstructural protein NSl expressed by baculovirus recombinant induces resistance to dengue virus encephalitis. J Virol 62: 3027PubMedGoogle Scholar
  15. 15.
    Falgout B, Bray M, Schlesinger J, Lai CJ (1990) Immunization of mice with recombinant vaccinia virus expressing dengue virus nonstructural protein NS1 protects against lethal dengue encephalitis. J Virol 64: 4356PubMedGoogle Scholar
  16. 16.
    Mason PW, Pincus S, Foumier MJ, Mason TL, Shope RE, Paoletti E (1991) Japanese encephalitis virus-vaccinia recombinants produce particulate forms of the structural membrane proteins and induce high levels of protection against lethal JEV infection. Virology 180: 294PubMedCrossRefGoogle Scholar
  17. 17.
    Men R, Bray M, Lai CJ (1991) Carboxy-terminally truncated dengue virus envelope glycoproteins expressed on the cell surface and secreted extracellularly exhibit increased immunogenicity in mice. J Virol 65: 1400PubMedGoogle Scholar
  18. 18.
    Deubel V, Bordier M, Megret F, Gentry MK, Schlesinger JJ, Girard M (1991) Processing, secretion, and irnmunoreactivity of carboxy terminally truncated dengue-2 virus envelope proteins expressed in insect cells by recombinant baculoviruses. Virology 180: 442PubMedCrossRefGoogle Scholar
  19. 19.
    Lai CJ, Zhao Z, Hori H, Bray M (1991) Infectious RNA transcribed from stably cloned full-length cDNA of dengue type 4 virus. Proc Natl Acad Sci (USA) (in press)Google Scholar
  20. 20.
    Hoke CH, Nisalak A, Sangawhipa N, Jatanasen S, Laorakapongse T, Innis BL, Kotchasenee S, Gingrich JB, Latendresse J, Fukai K, Burke DS (1988) Protection against Japanese encephalitis by inactivated vaccines. N Engl J Med 319: 608PubMedCrossRefGoogle Scholar
  21. 21.
    Xin YY, Ming ZG, Peng GY, Jian A, Min LH (1988) Safety of a live-attenuated Japanese encephalitis virus vaccine (SA14–14–2) for children. Am J Trop Med Hyg 39: 214PubMedGoogle Scholar
  22. 22.
    Eckels KH, Yong-Xin Y, Dubois DR, Marchette NJ, Trent DW, Johnson AJ (1988) Japanese encephalitis virus live-attenuated vaccine, Chinese strain SA14–14–2; adaptation to primary canine kidney cell cultures and preparation of a vaccine for human usc. Vaccine 6: 513PubMedCrossRefGoogle Scholar
  23. 23.
    Nitayaphan S, Grant JA, Chang G -J, Trent DW (1990) Nucleotide sequence of the virulent SA-14 strain of Japanese encephalitis virus and its attenuated vaccine derivative, SA14–14–2. Virology 177: 541PubMedCrossRefGoogle Scholar
  24. 24.
    Sumiyoshi H, Mori C, Fuke I, Morita K, Kuhara S, Kondou J, Kikuchi Y, Nagamatu H, Igarashi A (1987) Complete nucleotide sequence of the Japanese encephalitis virus genome RNA. Virology 161: 497PubMedCrossRefGoogle Scholar
  25. 25.
    Tice TR, Cowsar DR (1984) Biodegradable controlled release parenteral systems. Pharmacol Technol J 8: 26Google Scholar
  26. 26.
    DeCock KM, Monath TP, Nasidi A, Tukei PM, Enriquez J, Lichfield P, Craven RB, Fabiyi A, Okafor BC, Ravaonjanahary C, Sorungbe A (1988) Epidemic yellow fever in eastern Nigeria, 1986. Lancet 1: 630CrossRefGoogle Scholar
  27. 27.
    Nasidi A, Monath TP, DeCock K, Tomori O, Cordellier R, Olaleye OD, Harry TO, Adeniyi JA, Sorungbe AO, Ajose-Coker AO, van der Laan G, Oyediran ABO (1989) Urban yellow fever epidemic in western Nigeria, 1987. Trans R Soc Trop Med Hyg 83: 401PubMedCrossRefGoogle Scholar
  28. 28.
    Monath, TP, Nasidi A.Should yellow fever vaccine be a part of the Expanded Programme of Immunization in Africa? A cost-effectiveness analysis for Nigeria. Bull. WHO (submitted)Google Scholar
  29. 29.
    Hall AJ, Greenwood BM, Whittle H (1990) Modern Vaccines. Practice in developing countries. Lancet 335: 774PubMedCrossRefGoogle Scholar
  30. 30.
    Khanum S, Uddin N, Mann G, Tomkins A (1987) Comparison of Edmonston-Zagreb and Schwarz strains of mneasles vacine given by aerosol or subcutaneous injection. Lancet 1: 150PubMedCrossRefGoogle Scholar
  31. 31.
    Monath TP, Kinney RM, Schlesinger JJ, Brandriss MW, Bres P (1983) Ontogeny of yellow fever 17D vaccine: RNA olgonucleotide fingerprint and monoclonal antibody analysis of vaccines produced worldwide. J Gen Virol 64: 627PubMedCrossRefGoogle Scholar
  32. 32.
    Liprandi F (1981) Isolation of plaque variants differing in virulence from the 17D strain of yellow fever virus. J Gen Virol 56: 363PubMedCrossRefGoogle Scholar
  33. 33.
    Gould EA, Buckley A, Cane PA, Higgs S, Cammack N (1989) Use of a monoclonal antibody specific for wild-type yellow fever virus to identify a wild-type antigenic variant in 17D vaccine pools. J Gen Virol 70: 1889PubMedCrossRefGoogle Scholar
  34. 34.
    Hahn CS, Dalrymple JM, Strauss JH, Rice CM (1987) Comparison of the virulent Asibi strain of yellow fever virus with the 17D vaccine strain derived from it. Proc Natl Acad Sei (USA) 84: 2019CrossRefGoogle Scholar
  35. 35.
    Rice CM, Grakoui A, Galler R, Chambers TJ (1989) Transcription of infectious virus RNA from full-length cDNA templates produced by in vitro ligation. New Biology 1: 285Google Scholar
  36. 36.
    Robbins A, Freeman P (1988) Obstacles to developing vaccines for the Third World. Sei Am 259: 126Google Scholar
  37. 37.
    Bloom BR, Cerami A (eds) (1989) Biomedical science and the third world. Under the volcano. Ann NYAcad Sci 569: 1Google Scholar

Copyright information

© Springer Science+Business Media New York 1992

Authors and Affiliations

  • Thomas P. Monath
    • 1
  1. 1.Virology DivisionU. S. Army Medical Research Institute of Infectious DiseasesFrederickUSA

Personalised recommendations